Proactive Investors - Finance
11 Apr 2026, 11:27 UTC · 26w ago
Verdict
Headline takes no side. We score BIVI +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 90% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
BioVie expects to report topline data from its standalone bezisterim study for early-stage Parkinson's disease before the end of June.
More positive than 94% of claims this week
A previous clinical study showed that bezisterim used alongside levodopa improved muscle control compared to levodopa alone.
Continue reading
5 related stories
More positive than 80% of claims this week
BioVie has completed patient enrollment for its ADDRESS-LC Phase 2 study evaluating bezisterim for neurological symptoms of Long COVID.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company reported encouraging clinical results for bezisterim and the completion of patient enrollment for another trial, with an upcoming data catalyst.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Barrons
3h ago
−11.9%
Price is moving against the score
$1.19 vs $1.35 close before publication (Apr 10) · not market-adjusted
BIVI chart →
